









Markets
/
Stocks
/
nasdaq-pepg
/

PepGen Inc

PEPG

View Detailed Chart

1.320USD

0.0000.00%

Close 08/01, 16:00（ET）Quotes delayed by 15 min

43.19MMarket Cap

LossP/E TTM



PepGen Inc

1.320

0.0000.00%

Overview Company Financials

Financials

Intraday

30m

Today

-3.65%

5 Days

-8.97%

1 Month

+8.20%

6 Months

+5.60%

Year to Date

-65.17%

1 Year

-86.54%

View Detailed Chart

Agency Rating

Analyst Rating

Based on 5 analysts

BUY

Current Rating

8.000

Target Price

506.06%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

552

Total

Median

Average

Company name

Ratings

Analysts

PepGen Inc

PEPG

CRISPR Therapeutics AG

CRSP

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

Ionis Pharmaceuticals Inc

IONS

IQVIA Holdings Inc

IQV

...

111

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

15m

30m

15m

30m

D

Sell

Sell(9)

Neutral(2)

Buy(1)

Indicators

Sell(3)

Neutral(2)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

0.011

Buy

RSI(14)

47.033

Neutral

STOCH(KDJ)(9,3,3)

37.801

Sell

ATR(14)

0.087

Low Volatility

CCI(14)

-68.671

Neutral

Williams %R

60.000

Sell

TRIX(12,20)

0.326

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

1.376

Sell

MA10

1.395

Sell

MA20

1.321

Sell

MA50

1.375

Sell

MA100

1.467

Sell

MA200

2.788

Sell

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

PepGen Inc. is a clinical-stage biotechnology company. The Company is engaged in advancing the next generation of oligonucleotide therapeutics with the goal of transforming the treatment of severe neuromuscular and neurologic diseases. Its proprietary enhanced delivery oligonucleotide (EDO), platform leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake and nuclear delivery. Using these EDO peptides, the Company is generating a pipeline of oligonucleotide therapeutic candidates that are designed to target the root cause of serious diseases. The Company’s pipeline consists of two clinical stage programs: PGN-EDO51 for duchenne muscular dystrophy (DMD) patients who are amenable to exon 51-skipping and PGN-EDODM1 for myotonic dystrophy type 1 (DM1) patients. It also has three additional preclinical stage programs: PGN-EDO53, PGN-EDO45 and PGN-EDO44.

Ticker SymbolPEPG

CompanyPepGen Inc

CEODr. James G. Mcarthur, Ph.D.

Websitehttps://pepgen.com